专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1998007441A1 ALLOGENEIC HISTOCOMPATIBILITY COMPLEXES AS MEDIATORS OF CELL DESTRUCTION 审中-公开
标题翻译：作为细胞破坏剂的中和剂的异源组氨酸复合物
公开(公告)号：WO1998007441A1
公开(公告)日：1998-02-26
申请号：PCT/US1997014814
申请日：1997-08-22
申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY , THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
发明人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY , THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS , EISEN, Herman, N. , KRANZ, David, M.
IPC分类号： A61K38/17
CPC分类号： C07K14/70539 , A61K38/00 , A61K47/551 , A61K47/64
摘要： Methods are disclosed of producing and using Major Histocompatibility Complex (MHC) proteins, in native, truncated of fusion forms, complexed with MHC binding peptides and conjugated to targeting molecules, in order to target selected cells in a subject for T cell mediated destruction in vivo. The MHC proteins are chosen so to be allogeneic with respect to the host and the targeting molecules are chosen to selectively bind to the target cells. Pharmaceutical preparations including the targeted peptide-MHC complexes are also disclosed.
摘要翻译：公开了生产和使用与MHC结合肽复合并与靶向分子复合的天然的截短的融合形式的主要组织相容性复合物（MHC）蛋白的方法，以靶向受试者中选定的细胞，用于体内T细胞介导的破坏。 MHC蛋白被选择为相对于宿主是同种异体的，并且选择靶向分子以选择性地结合靶细胞。还公开了包括靶向肽-MHC复合物的药物制剂。

2. 发明申请

WO1991018629A1 METHOD FOR MODULATING SELF-DESTRUCTION OF CYTOLYTIC LYMPHOCYTES 审中-公开
标题翻译：用于调节自体淋巴细胞自体分离的方法
公开(公告)号：WO1991018629A1
公开(公告)日：1991-12-12
申请号：PCT/US1991003954
申请日：1991-06-05
申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY
发明人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY , WALDEN, Peter, R. , EISEN, Herman, N.
IPC分类号： A61K45/05
CPC分类号： A61K38/1787 , A61K38/1796 , G01N33/5047
摘要： Cytotoxic thymus derived lymphocytes, in the absence of other cells, are destroyed by exposing them to their cognate peptides (those that are presented by class I major histocompatibility complex (MHC-I) proteins for recognition by a T cell's antigen-specific receptors). The destruction is proportional to peptide concentration; it can be specifically prevented by a second peptide that competes with the cognate peptide for presentation by the CTL's MHC-I protein; and it is probably due primarily to self-destruction of individual CTLs (suicide) rather than to the destruction of some CTLs by others of the same clone in the same culture (fratricide). The method can be used in vivo, or in vitro, using cognate peptides to eliminate selected CTL clones that cause pathological cell destruction, as in some autoimmune diseases and some viral infections.
摘要翻译：在不存在其他细胞的情况下，细胞毒性胸腺衍生淋巴细胞通过将其暴露于其同源肽（由I类主要组织相容性复合物（MHC-1）蛋白质呈现，由T细胞的抗原特异性受体识别）中被破坏。破坏与肽浓度成正比; 可以通过与CTL的MHC-1蛋白质呈现相关肽的第二种肽特异性地预防它; 这可能主要是由于个体CTL（自杀）的自我毁灭，而不是由同一文化中的其他克隆（兄弟姊妹）破坏某些CTL。该方法可以在体内或体外使用，使用同源肽来消除导致病理细胞破坏的所选CTL克隆，如在一些自身免疫疾病和一些病毒感染中。

3. 发明申请

WO2005085443A2 RNAI-BASED THERAPEUTICS FOR ALLERGIC RHINITIS AND ASTHMA 审中-公开
标题翻译：基于RNAI的过敏性胃炎和哮喘的治疗方法
公开(公告)号：WO2005085443A2
公开(公告)日：2005-09-15
申请号：PCT/US2005/006445
申请日：2005-03-01
申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY , CHEN, Jianzhu , EISEN, Herman, N. , GE, Qing
发明人： CHEN, Jianzhu , EISEN, Herman, N. , GE, Qing
IPC分类号： C12N15/11
CPC分类号： C12N15/113 , C12N15/111 , C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2320/32
摘要： The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of allergic rhinitis and/or asthma. In certain embodiments of the invention the RNAi agent is targeted to a transcript that encodes a protein selected from the group consisisting of the FCεRIα chain, the FCεRIβ chain, c-Kit, Lyn, Syk, ICOS, OX40L, CD40, CD80, CD86, RelA, RelB, 4-1BB ligand, TLR1, TLR2, TLR3,TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, CD83, SLAM, common γ chain, and COX-2. In addition, the invention provides RNAi agent/delivery agent compositions and methods of use. In certain embodiments of the invention compositions comprising an RNAi agent are delivered by the respiratory route.
摘要翻译：本发明提供包含用于治疗由（例如，特征为IgE介导的超敏反应）介导的病症和疾病的一种或多种RNAi试剂（例如siRNA，shRNA或RNAi载体）的组合物，以及用于鉴定有效的RNAi试剂的系统以此目的。该组合物适用于治疗过敏性鼻炎和/或哮喘。在本发明的某些实施方案中，RNAi试剂靶向编码选自FCεRIα链，FCεRIbeta链，c-Kit，Lyn，Syk，ICOS，OX40L，CD40，CD80，CD86， RelA，RelB，4-1BB配体，TLR1，TLR2，TLR3，TLR4，TLR5，TLR6，TLR7，TLR8，TLR9，CD83，SLAM，通用γ链和COX-2。此外，本发明提供RNAi剂/递送剂组合物和使用方法。在本发明的某些实施方案中，包含RNAi试剂的组合物通过呼吸途径递送。

4. 发明申请

WO2004029213A2 COMPOSITIONS AND METHODS FOR DELIVERY OF SHORT INTERFERING RNA AND SHORT HAIRPIN RNA 审中-公开
标题翻译：用于递送短暂干扰RNA和短毛发RNA的组合物和方法
公开(公告)号：WO2004029213A2
公开(公告)日：2004-04-08
申请号：PCT/US2003/030508
申请日：2003-09-29
申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY , CHEN, Jianzhu , EISEN, Herman, N. , GE, Qing
发明人： CHEN, Jianzhu , EISEN, Herman, N. , GE, Qing
IPC分类号： C12N
CPC分类号： C12N15/1131 , A61K9/5146 , A61K9/5153 , A61K38/00 , C12N15/111 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2320/32 , C12N2799/021
摘要： The present invention provides compositions comprising an RNAi-inducing entity any of a variety of different delivery agents. Preferred RNAi-inducing agents include siRNA, shRNA, and RNAi-inducing vectors. Preferred delivery agents include cationic polymers, modified cationic polymers, lipids, and surfactants suitable for introduction into the lung. The invention further provides methods of inhibiting expression of a target 10 transcript in a mammal and methods of treating or preventing a disease or condition in a mammal by administration of the compositions.
摘要翻译：本发明提供包含多种不同递送剂的RNAi诱导实体的组合物。优选的RNAi诱导剂包括siRNA，shRNA和RNAi诱导载体。优选的递送剂包括阳离子聚合物，改性阳离子聚合物，脂质和适用于引入肺的表面活性剂。本发明还提供抑制哺乳动物中靶标10转录物的表达的方法以及通过施用组合物来治疗或预防哺乳动物的疾病或病症的方法。

5. 发明申请

WO2004028471A2 INFLUENZA THERAPEUTIC 审中-公开
标题翻译：流感治疗
公开(公告)号：WO2004028471A2
公开(公告)日：2004-04-08
申请号：PCT/US2003/030502
申请日：2003-09-29
申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY , CHEN, Jianzhu , EISEN, Herman, N. , GE, Qing
发明人： CHEN, Jianzhu , EISEN, Herman, N. , GE, Qing
IPC分类号： A61K
CPC分类号： C12N15/1131 , A61K9/5146 , A61K9/5153 , A61K38/00 , C12N15/111 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12N2320/32 , C12N2799/021
摘要： The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza.
摘要翻译：本发明提供了用于基于RNA干扰（RNAi）现象抑制流感感染和/或复制的方法和组合物以及用于鉴定用于抑制流感病毒的有效siRNA和shRNA以及用于研究流感病毒感染机制的系统的系统。本发明还提供用于抑制感染，致病性和/或其他感染因子的复制的方法和组合物，特别是感染可以从身体外部直接接近的细胞的感染，例如皮肤细胞或粘膜细胞的方法和组合物。此外，本发明提供了包含RNAi诱导实体的组合物，例如靶向流感病毒转录物的siRNA，shRNA或RNAi诱导载体和各种递送试剂中的任一种。本发明还包括使用该组合物治疗流感的方法。

6. 发明申请

WO2006102461A2 INFLUENZA THERAPEUTIC 审中-公开
标题翻译：流感治疗
公开(公告)号：WO2006102461A2
公开(公告)日：2006-09-28
申请号：PCT/US2006/010491
申请日：2006-03-22
申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY , CHEN, Jianzhu , GE, Qing , EISEN, Herman, N.
发明人： CHEN, Jianzhu , GE, Qing , EISEN, Herman, N.
IPC分类号： A61K38/00 , A61K48/00 , C12N15/11 , C12N15/113
CPC分类号： A61K9/5146 , A61K9/5153 , A61K38/00 , C12N15/111 , C12N15/1131 , C12N2310/111 , C12N2310/14 , C12N2310/321 , C12N2310/53 , C12N2320/11 , C12N2320/32 , C12N2799/021 , C12N2310/3521
摘要： The present invention provides compositions comprising an RNAi-inducing entity targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for inhibiting a biological activity of an influenza virus and/or for treatment or prevention of influenza. The invention provides target portion sequences that are favorably conserved for RNAi across a plurality of influenza virus A strains isolated from human hosts and/or avian hosts and RNAi-inducing entities, e.g., siRNAs and shRNAs, targeted to such favorably conserved target portions. The invention provides a variety of nucleic acids comprising sequences identical or complementary to at least a portion of one or more of these favorably conserved target portion sequences. The invention further provides methods and compositions for delivering RNAi-inducing agents to an organ or tissue of a mammalian subject, e.g., to the lung. Methods of diagnosing influenza and determining the susceptibility of an influenza virus to inhibition by an RNAi-inducing agent are also provided. Transgenic animals that express an RNAi-inducing agent targeted to an influenza gene are another aspect of the invention.
摘要翻译：本发明提供了包含针对流感病毒转录物的RNAi诱导实体和各种递送试剂中的任一种的组合物。本发明还包括使用该组合物抑制流感病毒的生物活性和/或用于治疗或预防流感的方法。本发明提供了针对分离自人宿主和/或禽类宿主和RNAi诱导实体（例如siRNA和shRNA）的多个流感病毒A菌株的RNAi有利地保守的靶标部分序列，靶向这些有利的保守靶部分。本发明提供了多种核酸，其包含与这些有利保守的靶部分序列中的一种或多种的至少一部分相同或互补的序列。本发明进一步提供了用于将RNAi诱导剂递送至哺乳动物受试者的器官或组织例如肺的方法和组合物。还提供了诊断流感并确定流感病毒对RNAi诱导剂抑制的易感性的方法。表达针对流感基因的RNAi诱导剂的转基因动物是本发明的另一方面。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式